NORML PAC is endorsing Assemblywoman Bonnie Watson Coleman in her campaign to be elected to the United States Congress representing the 12th Congressional District in New Jersey.
“Assemblywoman Bonnie Watson Coleman has been a proponent of reforming New Jersey’s marijuana laws during her time in Trenton. She voted in support of legalizing medical marijuana in New Jersey, co-sponsored legislation to decriminalize possession of marijuana in the garden state, and supports a move to the legalization and regulation of marijuana,” stated NORML PAC Manager Erik Altieri, “Voters in New Jersey’s 12th Congressional District should vote to send her to Congress where she will be a great asset in pursuing reform at the national level.”
Bonnie Watson Coleman was named by MSNBC as one of the 30 women candidates to watch in 2014 and was named one of the top five female pro-marijuana candidates in Freedom Leaf Magazine.
The marijuana voter initiative that is almost guaranteed to pass on November 4th is DC Initiative 71, the “Legalization of Possession of Minimal Amounts of Marijuana for Personal Use Act of 2014.” However, as we will discuss, it is far from certain when the provisions of this proposal will take effect.
Readers should first understand that the District of Columbia is not a state; rather it is a special district created in 1790 by Congress from land along the Potomac River, formerly part of the states of Maryland and Virginia, as the seat of our national government. In 1973 the Congress gave the District a limited form of local control, called the Home Rule Charter, which provides for an elected mayor and City Council, which have the authority to enact and enforce local laws. However, any legislation passed by the City Council is reviewable by the Congress, which has 60 legislative days (when Congress is actually in session) to review and amend or reject the proposed legislation. Those same limitations apply to voter initiatives enacted in the District. In addition, under the Home Rule Charter, voter initiatives may not mandate the expenditure of city funds.
That background is necessary to understand the limited nature of the legalization proposal currently on the ballot for DC voters.
What Initiative 71 Would Do
Initiative 71, sponsored by the DC Cannabis Campaign, would eliminate all criminal and civil penalties for adults, making it legal to:
possess up to two ounces of marijuana for personal use;
grow no more than six cannabis plants (with three or fewer being mature, flowering plants) within the person’s principal residence;
transfer without payment (but not sell) up to one ounce of marijuana to another person 21 years of age or older; and
use or sell drug paraphernalia for the use, growing or processing of marijuana or cannabis.
Initiative 71 does not attempt to establish legal marijuana dispensaries, as that would run afoul of the home rule prohibition on voter initiatives mandating the expenditure of city funds. And it does not protect marijuana smokers against job discrimination, nor alter the child custody issues pertaining to the use of marijuana or the DUID laws in the District.
Moderate cannabis consumption by young people is not positively associated with changes in intelligence quotient (IQ), according to data presented this week at the European College of Neuropsychopharmacology annual congress in Berlin, Germany.
Investigators at the University College of London analyzed data from 2,612 subjects who had their IQ tested at the age of eight and again at age 15. They reported no relationship between cannabis use and lower IQ at age 15 when confounding factors such as subjects’ history of alcohol use and cigarette use were taken into account.
“In particular alcohol use was found to be strongly associated with IQ decline,” the authors wrote in a press release cited by The Washington Post. “No other factors were found to be predictive of IQ change.”
Quoted in the Independent Business Times, the study’s lead author said: “Our findings suggest cannabis may not have a detrimental effect on cognition, once we account for other related factors particularly cigarette and alcohol use. This may suggest that previous research findings showing poorer cognitive performance in cannabis users may have resulted from the lifestyle, behavior and personal history typically associated with cannabis use, rather than cannabis use itself.”
The investigators acknowledged that more chronic marijuana use, defined in the study as a subject’s admission of having consumed cannabis 50 times or more by age 15, was correlated with slightly poorer exam results at the age of 16 — even after controlling for other variables. However, investigators admitted: “It’s hard to know what causes what. Do kids do badly at school because they are smoking weed, or do they smoke weed because they’re doing badly?”
Commenting on the newly presented data, the meeting’s Chair, Guy Goodwin, from the University of Oxford, told BBC News: “This is a potentially important study because it suggests that the current focus on the alleged harms of cannabis may be obscuring the fact that its use is often correlated with that of other even more freely available drugs and possibly lifestyle factors.”
In a recent review published in the New England Journal of Medicine, the NIDA Director Nora Volkow alleged that cannabis use, particularly by adolescents, is associated with brain alterations and lower IQ. However, the IQ study cited by Ms. Volkow as the basis of her claim was later questioned in a separate analysis published in the Proceedings of the National Academy of Sciences. That paper suggested that socioeconomics, not subjects’ cannabis use, was responsible for differences in IQ and that the plant’s “true effect [on intelligence quotient] could be zero.”
A previous assessment of cannabis use and its potential impact on intelligence quotient in a cohort of young people tracked since birth reported, “[M]arijuana does not have a long-term negative impact on global intelligence.”
Federal District Court Judge Asks: Should Federal Law Classify Cannabis As One Of The Nation’s Most Dangerous Drugs?October 20, 2014
Testimony regarding the constitutionality of the federal statute designating marijuana as a Schedule I Controlled Substance will be taken on Monday, October 27 in the United States District Court for the Eastern District of California in the case of United States v. Pickard, et. al., No. 2:11-CR-0449-KJM.
Members of Congress initially categorized cannabis as a Schedule I substance, the most restrictive classification available, in 1970. Under this categorization, the plant is defined as possessing “a high potential for abuse, … no currently accepted medical use in treatment in the United States, … [and lacking] accepted safety for … use … under medical supervision.”
Expert witnesses for the defense – including Drs. Carl Hart, Associate Professor of Psychology in the Department of Psychiatry and Psychology at Columbia University in New York City, retired physician Phillip Denny, and Greg Carter, Medical Director of St. Luke’s Rehabilitation Institute in Spokane, Washington – will testify that the accepted science is inconsistent with the notion that cannabis meets these Schedule I criteria.
“[I]t is my considered opinion that including marijuana in Schedule I of the Controlled Substances Act is counter to all the scientific evidence in a society that uses and values empirical evidence,” Dr. Hart declared. “After two decades of intense scientific inquiry in this area, it has become apparent the current scheduling of cannabis has no footing in the realities of science and neurobiology.”
The government intends to call Bertha Madras, Ph.D., Professor of Psychobiology at Harvard Medical School and the former Deputy Director for Demand Reduction for the White House Office of National Drug Control Policy under President George W. Bush.
Additional evidence has been presented by way of declarations by Marine Sgt. Ryan Begin, a veteran of the Iraq War; Jennie Stormes, the mother of a child suffering from Dravet Syndrome – a pediatric form of epilepsy that has been shown in preliminary trials to respond to specific compounds in the cannabis plant; James Nolan, Ph.D. an associate professor of sociology and anthropology at West Virginia University and a former crime analyst for the US Federal Bureau of Investigation; and Christopher Conrad, noted cannabis author, archivist, and cultivation expert.
This is the first time in recent memory that a federal judge has granted an evidentiary hearing on a motion challenging the statute which classifies cannabis to be one of the most dangerous illicit substances in the nation. Attorneys Zenia Gilg and Heather Burke, both members of the NORML Legal Committee, contend that the federal government’s present policies facilitating the regulated distribution of cannabis in states such as Colorado and Washington can not be reconciled with the insistence that the plant is deserving of its Schedule I status under federal law.
They write: “In effect, the action taken by the Department of Justice is either irrational, or more likely proves the assertions made in Part I (B) of this Brief: marijuana does not fit the criteria of a Schedule I Controlled Substance.”
Speaking recently in a taped interview with journalist Katie Couric, United States Attorney General Eric Holder expressed the need to revisit cannabis’ Schedule I placement under federal law. Holder said, “[T]he question of whether or not they should be in the same category is something that I think we need to ask ourselves, and use science as the basis for making that determination.”
The testimonial part of the evidentiary hearing in United States v. Pickard, et. al., is expected to last three days.
On November 4, Florida voters will have the opportunity to vote on an amendment to their state constitution, Amendment 2, to establish a medical marijuana program in that state. This vote is especially important as it would be the first southern state to legalize medical use, and would likely encourage other states in the region to take a serious look at the use of marijuana as a medicine for seriously ill patients.
Why A Constitutional Amendment?
Fearful that the conservative Republican state legislature would have passed legislation overriding such a change, if it were simply a state law changed by voter initiative, People United for Medical Marijuana, the sponsor of this proposal, elected to try to include the policy changes as an amendment to the state constitution. Amendment 2, the Use of Marijuana for Certain Medical Conditions initiative, must therefore receive 60 percent of votes cast to be enacted as a constitutional amendment, a high goal and a real challenge for any proposal to meet. That decision is one that may be instructive for future voter initiatives, with most polls currently showing we will win a majority of votes, but likely less than 60 percent.